4.01
price down icon0.99%   -0.04
after-market Handel nachbörslich: 4.10 0.09 +2.24%
loading

C 4 Therapeutics Inc Aktie (CCCC) Neueste Nachrichten

pulisher
04:15 AM

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

04:15 AM
pulisher
Nov 20, 2024

C4 Therapeutics appoints Steve Hoerter to board - Investing.com

Nov 20, 2024
pulisher
Nov 20, 2024

C4 Therapeutics appoints Steve Hoerter to board By Investing.com - Investing.com UK

Nov 20, 2024
pulisher
Nov 20, 2024

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors - The Bakersfield Californian

Nov 20, 2024
pulisher
Nov 20, 2024

C4 Therapeutics Adds Oncology Veteran Steve Hoerter to Board, Brings Drug Launch Expertise | CCCC Stock News - StockTitan

Nov 20, 2024
pulisher
Nov 20, 2024

C4 Therapeutics, Inc. Appoints Steve Hoerter as Board of Directors - Marketscreener.com

Nov 20, 2024
pulisher
Nov 19, 2024

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Nov 19, 2024
pulisher
Nov 18, 2024

Stephens Initiates Coverage on C4 Therapeutics (NASDAQ:CCCC) - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Stephens & Co. Initiates Coverage of C4 Therapeutics (CCCC) with Equal-Weight Recommendation - MSN

Nov 18, 2024
pulisher
Nov 16, 2024

C4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Large Drop in Short Interest - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Nov 15, 2024
pulisher
Nov 15, 2024

Orbimed Advisors LLC Increases Stake in C4 Therapeutics Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk - Simply Wall St

Nov 15, 2024
pulisher
Nov 13, 2024

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 13, 2024
pulisher
Nov 11, 2024

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 11, 2024
pulisher
Nov 11, 2024

Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 11, 2024
pulisher
Nov 08, 2024

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Nov 08, 2024
pulisher
Nov 08, 2024

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Nov 08, 2024
pulisher
Nov 06, 2024

C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout - Seeking Alpha

Nov 06, 2024
pulisher
Nov 06, 2024

CCCCC4 Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 06, 2024
pulisher
Nov 06, 2024

C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

C4 Therapeutics Launches Phase 1 Trial in China: $357M Cancer Drug Partnership Advances | CCCC Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 05, 2024

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 05, 2024
pulisher
Nov 05, 2024

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Nov 05, 2024
pulisher
Nov 05, 2024

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma At the American Society of Hematology Annual Meeting - Marketscreener.com

Nov 05, 2024
pulisher
Nov 05, 2024

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at the American Society of Hematology (ASH) Annual Meeting - The Manila Times

Nov 05, 2024
pulisher
Nov 05, 2024

C4 Therapeutics' Cemsidomide Trial Data Selected for Key ASH Presentations in NHL, Myeloma | CCCC Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Nov 05, 2024
pulisher
Nov 04, 2024

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Nov 04, 2024
pulisher
Nov 04, 2024

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 04, 2024
pulisher
Nov 04, 2024

Will C4 Therapeutics' Upcoming Multiple Myeloma And NHL Trial Results Drive Stock Recovery? - RTTNews

Nov 04, 2024
pulisher
Nov 01, 2024

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 01, 2024
pulisher
Nov 01, 2024

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 01, 2024
pulisher
Nov 01, 2024

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 01, 2024
pulisher
Nov 01, 2024

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 01, 2024
pulisher
Nov 01, 2024

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com

Nov 01, 2024
pulisher
Nov 01, 2024

C4 Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 01, 2024
pulisher
Nov 01, 2024

C4 Therapeutics Advances in Protein Degradation Therapy - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

C4 Therapeutics (CCCC) Q3 2024 Earnings: Revenue Surges to $15.4M, GAAP EPS Loss Narrows to $0.35 - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Oct 31, 2024
pulisher
Oct 31, 2024

C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

C4 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Oct 31, 2024
pulisher
Oct 31, 2024

C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Oct 31, 2024
pulisher
Oct 29, 2024

We're Hopeful That C4 Therapeutics (NASDAQ:CCCC) Will Use Its Cash Wisely - Yahoo Finance

Oct 29, 2024
pulisher
Oct 29, 2024

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Oct 29, 2024
pulisher
Oct 26, 2024

C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update - MarketBeat

Oct 26, 2024
pulisher
Oct 25, 2024

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Citizentribune

Oct 25, 2024
pulisher
Oct 17, 2024

C4 Therapeutics appoints Paige Mahaney as new CSO - Investing.com India

Oct 17, 2024
pulisher
Oct 16, 2024

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 16, 2024
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.55%
$367.36
price up icon 0.83%
$194.56
price up icon 0.15%
$108.23
price up icon 5.96%
Kapitalisierung:     |  Volumen (24h):